BERLIN (dpa-AFX) - Flourishing pharmaceutical sales and robust international business propelled specialty pharma company Medios in the third quarter. Revenue rose by approximately nine percent year-on-year to just over EUR538 million in the three months to the end of September, the SDax-listed company announced Tuesday in Berlin. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) amounted to around EUR24 million, about two and a half percent below the previous year's level--though at that time, Medios had reported a record figure due to a one-off positive inflation-related effect.

After taxes, however, profit for the current reporting period surged to EUR7.2 million, up from about EUR4 million previously. Medios benefited in part from lower special effects. The management team, led by outgoing CEO Matthias Gärtner, confirmed its annual targets. As previously announced, Gärtner will leave Medios at the end of the year, with his successor Thomas Meier set to take over as CEO on February 1./tav/mis